Pioglitazone

Mechanism

Pharmacological Class and Group

Thiazolidinedione (TZD), classified pharmacologically as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ).

Mechanism of Action

Unlike sulfonylureas, TZDs do not stimulate pancreatic insulin secretion, but rather directly enhance peripheral cellular sensitivity to circulating insulin in skeletal muscle, adipose tissue, and liver.

Genomic Transcription Mechanism

1. Binding to the Nuclear Receptor PPAR-γ: Pioglitazone passively diffuses through the cell membrane and binds to the ligand binding domain of the nuclear receptor PPAR-γ, highly expressed in adipose tissue.

2. Heterodimerization with RXR: After ligand binding, the receptor undergoes a conformational change and forms a stable heterodimer with the Retinoid X Receptor (RXR):

Pioglitazone-PPAR-γ + RXR Heterodimeric Active Complex Binding to PPRE

3. Binding to Peroxisome Proliferator Response Elements (PPRE): The complex binds to specific DNA sequences promoting the recruitment of transcription coactivators and deacetylases.

4. Modulation of Key Metabolism Genes:

• GLUT4: Increases the expression and membrane translocation of the insulin-dependent glucose transporter in myocytes and adipocytes (net increase in glucose uptake).
• Adiponectin: Increases levels of circulating adiponectin, a sensitizing and anti-inflammatory molecule.
• TNF-α and Resistin: Decreases the transcription of these proinflammatory cytokines that cause peripheral insulin resistance.
• Lipid Redistribution: Promotes the differentiation of preadipocytes into small, metabolite-active adipocytes in subcutaneous cellular tissue, removing toxic free fatty acids from the systemic circulation and the myocardium/liver (reduction of ectopic fatty deposits).

Pharmacokinetics

High Resolution Pharmacokinetics

• Absorption and Bioavailability: Rapid oral absorption. Bioavailability greater than 80%. Food intake slightly delays the maximum peak (T_max ≈ 3-4 hours) but does not reduce the total degree of absorption.
• Distribution: Small volume of distribution (0.63 L/kg). Extreme binding to plasma albumin (>99%).
• Metabolism: Massive first-pass hepatic metabolism mediated mainly by the cytochrome isoenzymes CYP2C8 and CYP3A4. It generates three main active metabolites: the keto derivative (M-III) and the hydroxy derivatives (M-IV and M-II). Systemic exposure to these active metabolites substantially exceeds that of the parent molecule.
• Excretion: Major elimination in the form of inactive metabolites conjugated with bile (15-45%) and feces. Less than 15% is recovered unchanged in urine.
• Half-life (t_1/2): Plasma half-life of pioglitazone 3 to 7 hours; Circulating active metabolites exhibit cumulative half-lives of 16 to 24 hours.

Indicators and dose

Clinical Indications and Off-Label Uses

• Type 2 Diabetes Mellitus: To improve glycemic control, particularly in patients with marked insulin resistance and metabolic syndrome phenotype.
• Non-alcoholic Steatohepatitis (MASH/NASH) (off-label / supported by clinical guidelines): Reduction of hepatic steatosis, lobular inflammation and cellular ballooning in patients with or without diabetes.
• Prevention of recurrent stroke (off-label): In patients with documented insulin resistance and recent history of ischemic stroke (based on the IRIS trial).

Dosage and Clinical Adjustment

Scheme in Adults:

• Initial Dose: 15 mg to 30 mg once daily orally, with or without food.
• Maintenance: Adjust dose gradually in steps of 15 mg every 4 weeks, according to patient tolerability and HbA1c levels.
• Maximum Dose: 45 mg once a day.

Adjustment in Renal Failure: No dose adjustment is required in patients with renal failure of any degree (even on maintenance dialysis). However, monitor the symptoms of fluid retention extremely carefully.

Adjustment in Liver Failure: It is not advisable to start treatment if baseline liver transaminases exceed 2.5 times the upper limit of normal.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Advanced congestive heart failure: NYHA Functional Class II, III or IV of any etiology (due to marked water retention).
• Severe active liver failure (TGP/AST > 3 times the upper limit of normal).
• Hypersensitivity to the drug.
• Personal history or active suspicion of bladder cancer.
• Macroscopic hematuria of unexplained origin.

Relative Contraindications

• Established senile osteoporosis or high risk of fractures in postmenopausal women.
• Active diabetic macular edema or uncontrolled proliferative retinopathy.

Adverse Effects (ADR) and Specific Toxicity

• Very common (>10%): Fluid retention and dose-dependent formation of peripheral edema (incidence of up to 15% in combined therapy with insulin).
• Frequent (1%-10%): Dilutional anemia (transient drop in hematocrit of 2-4% secondary to hemodilution due to water retention), weight gain of 2 to 5 kg (mixture of edema and increase in subcutaneous adipose tissue), headache, sinusitis, increase in reversible liver enzymes.
• Uncommon (0.1%-1%): Alteration of bone density with distal limb fractures (especially in the humerus, hand, foot in women, due to the suppression of osteoblastic activity mediated by PPAR-γ by favoring adipogenesis in the bone marrow to the detriment of osteoblastogenesis).
• Rare (0.01%-0.1%): Bladder cancer (epidemiological association debated, avoid exposure in patients with urothelial risk factors).

Critical Toxicity: Hydrosalin Retention and Heart Failure

TZDs increase active sodium reabsorption in the renal collecting duct by stimulating apical epithelial sodium channels (ENaC) through direct gene induction in the mineralocorticoid receptor. The volume expansion resulting from hemodilution is deleterious in patients with underlying left ventricular dysfunction.

ENaC stimulation ↑ Na reabsorption⁺ Expansion of plasma volume Decompensation of Heart Failure

The drug should be discontinued immediately if progressive dyspnea on exertion, orthopnea, jugular engorgement or bilateral lower limb edema appears.

Drug Interactions of Clinical Relevance

• Strong CYP2C8 inhibitors (Gemfibrozil, Clopidogrel): They drastically increase the plasma area under the curve (AUC) of pioglitazone by up to 3 times, potentiating the risks of fluid retention and severe hypoglycemia. Requires dose reduction to a minimum or suspension.
• CYP2C8 inducers (Rifampicin): They markedly decrease (up to 54%) the circulating therapeutic levels of pioglitazone, notably reducing its metabolic clinical efficacy.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Contraindicated. Preclinical studies reported delay in fetal bone development and induction of early embryonic death.
• Breastfeeding: Contraindicated. The drug is actively excreted in breast milk in animal models.